References
- Winiarska M, Bil J, Wilczek E, et al Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008;5:e64.
- Nowakowski GS, Maurer MJ, Habermann TM, et al Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010;28:412–417.
- Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 2003;31:779–783.
- Vitols S, Angelin B, Juliusson G. Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans–in vitro and in vivo studies. Lipids 1997;32:255–262.
- Endo A. The discovery and development of HMG-CoA reductase inhibitors. 1992. Atheroscler Suppl 2004;5:67–80.
- Weinberg JB, Volkheimer AD, Mihovilovic M, et al Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia. Leukemia 2008;22:2184–2192.
- Heintel D, Kienle D, Shehata M, et al High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 2005;19:1216–1223.
- Rasi S, Forconi F, Bruscaggin A, Sozzi E, Gaidano G, Rossi$146#D. Impact of the host genetic background on prognosis of chronic lymphocytic leukemia. Blood 2010;115:1106–1107.
- Sellick GS, Wade R, Richards S, Oscier DG, Catovsky D, Houlston RS. Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis. Blood 2008;111:1625–1633.
- MacIntyre DA, Jimenez B, Lewintre EJ, et al Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia 2010;24:788–797.
- Shanafelt TD, Rabe KG, Kay NE, et al Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:1233–1240.
- Cheson BD, Bennett JM, Grever M, et al National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.
- Weinberg JB, Volkheimer AD, Chen Y, et al Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. Am J Hematol 2007;82:1063–1070.
- Ahn KS, Sethi G, Aggarwal BB. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem Pharmacol 2008;75:907–913.
- Cuni S, Perez-Aciego P, Perez-Chacon G, et al A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004;18:1391–1400.